Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01266902 · ClinicalTrials.gov registry record · Phase 3
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
A Phase 3 study, sponsored by Janssen R&D Ireland.
- Completed
- Registry status
- Phase 3
- Development phase
- 482
- Enrollment target
NCT01266902 is a Phase 3 study that has completed, run by Janssen R&D Ireland. The registered enrollment target is 482 participants.
The verdict
NCT01266902, a Phase 3 study, has completed, sponsored by Janssen R&D Ireland.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 482 participants
- Enrollment target
Study Summary
The purpose of the study is to provide continued access to TMC278 in HIV-1 infected patients who were randomized and treated with TMC278 in the Phase IIb or Phase III trials.
Interventions
- DRUG Rilpivirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 482 participants |
| Start Date | 2011-02 |
| Est. Completion | 2020-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01266902
The ClinicalTrials.gov registry entry for NCT01266902 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 482 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen R&D Ireland, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rilpivirine is the first listed.
NCT01266902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01266902 about?
NCT01266902 is a clinical study titled "A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1". The purpose of the study is to provide continued access to TMC278 in HIV-1 infected patients who were randomized and treated with TMC278 in the Phase IIb or Phase III trials.
What is the current status of trial NCT01266902?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 482 participants. The study started on 2011-02. Estimated completion is 2020-02.
What interventions are being tested in trial NCT01266902?
The interventions under investigation include: Rilpivirine (DRUG).
Who is sponsoring clinical trial NCT01266902?
This trial is sponsored by Janssen R&D Ireland, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.